Your browser doesn't support javascript.
loading
Non-Persistence With Antiplatelet Medications Among Older Patients With Peripheral Arterial Disease.
Wawruch, Martin; Murin, Jan; Tesar, Tomas; Paduchova, Martina; Petrova, Miriam; Celovska, Denisa; Havelkova, Beata; Trnka, Michal; Aarnio, Emma.
Afiliação
  • Wawruch M; Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
  • Murin J; 1st Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
  • Tesar T; Department of Organization and Management of Pharmacy, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia.
  • Paduchova M; Department of Angiology, Health Centre, Trnava, Slovakia.
  • Petrova M; Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
  • Celovska D; 1st Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
  • Havelkova B; General Health Insurance Company, Bratislava, Slovakia.
  • Trnka M; Institute of Medical Physics, Biophysics, Informatics and Telemedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
  • Aarnio E; Institute of Biomedicine, University of Turku, Turku, Finland.
Front Pharmacol ; 12: 687549, 2021.
Article em En | MEDLINE | ID: mdl-34093210
ABSTRACT

Introduction:

Antiplatelet therapy needs to be administered life-long in patients with peripheral arterial disease (PAD). Our study was aimed at 1) the analysis of non-persistence with antiplatelet medication in older PAD patients and 2) identification of patient- and medication-related characteristics associated with non-persistence.

Methods:

The study data was retrieved from the database of the General Health Insurance Company. The study cohort of 9,178 patients aged ≥ 65 years and treated with antiplatelet medications was selected from 21,433 patients in whom PAD was newly diagnosed between 01/2012 and 12/2012. Patients with a 6 months treatment gap without antiplatelet medication prescription were classified as non-persistent. Characteristics associated with non-persistence were identified using the Cox regression.

Results:

At the end of the 5 years follow-up, 3,032 (33.0%) patients were non-persistent. Age, history of ischemic stroke or myocardial infarction, clopidogrel or combination of aspirin with clopidogrel used at the index date, higher co-payment, general practitioner as index prescriber and higher overall number of medications were associated with persistence, whereas female sex, atrial fibrillation, anxiety disorders, bronchial asthma/chronic obstructive pulmonary disease, being a new antiplatelet medication user (therapy initiated in association with PAD diagnosis), and use of anticoagulants or antiarrhythmic agents were associated with non-persistence.

Conclusion:

In patients with an increased probability of non-persistence, an increased attention should be paid to improvement of persistence.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article